“I am very pleased with our performance for the first nine months of 2026. Our growth initiatives have produced encouraging results, and we plan to continue building on this progress. In pharmaceuticals, we are in the process of determining which marketing efforts to deploy to increase awareness of Renacidin among healthcare professionals. In personal care, we have a new product in late-stage development that we plan to launch early next year. We are hopeful that our continued efforts will drive further growth and lead to increased sales.”
| Contact: | |
| (631) 273-0900 | |
| dvigilante@u-g.com | |
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
| Financial Results for the | ||||||||||||
| Three and Nine Months Ended | ||||||||||||
| STATEMENTS OF INCOME | ||||||||||||
| (unaudited) | ||||||||||||
| THREE MONTHS ENDED | NINE MONTHS ENDED | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Net sales | $ | 3,494,780 | $ | 2,264,261 | $ | 9,475,269 | $ | 7,583,613 | ||||
| Costs and expenses: | ||||||||||||
| Cost of sales | 1,619,479 | 1,311,192 | 4,629,733 | 3,775,122 | ||||||||
| Operating expenses | 644,539 | 620,893 | 1,978,784 | 1,947,678 | ||||||||
| Research and development expense | 121,834 | 117,104 | 361,250 | 339,366 | ||||||||
| Total costs and expenses | 2,385,852 | 2,049,189 | 6,969,767 | 6,062,166 | ||||||||
| Income from operations | 1,108,928 | 215,072 | 2,505,502 | 1,521,447 | ||||||||
| Other Income: | ||||||||||||
| Investment income | 72,556 | 75,165 | 212,815 | 230,425 | ||||||||
| Net (loss) gain on marketable securities | (7,916 | ) | 36,238 | 58,191 | 73,164 | |||||||
| Settlement income | --- | --- | 339,493 | --- | ||||||||
| Gain on sale of asset | --- | --- | 8,310 | --- | ||||||||
| Total other income | 64,640 | 111,403 | 618,809 | 303,589 | ||||||||
| Income before provision for income taxes | 1,173,568 | 326,475 | 3,124,311 | 1,825,036 | ||||||||
| Provision for income taxes | 242,656 | 58,034 | 645,918 | 368,874 | ||||||||
| Net income | $ | 930,912 | $ | 268,441 | $ | 2,478,393 | $ | 1,456,162 | ||||
| Earnings per common share (Basic and Diluted) | $ | 0.20 | $ | 0.06 | $ | 0.54 | $ | 0.32 | ||||
| Weighted average shares (Basic and Diluted) | 4,594,319 | 4,594,319 | 4,594,319 | 4,594,319 | ||||||||
Source: 